Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Advertising

Press Releases

38 Press Releases
DateTitleCompany
08 Nov 17 National Survey Reveals Majority of Women Newly Diagnosed with Multiple Sclerosis Have Concerns They Aren’t Discussing with Their Healthcare Team Teva Pharmaceutical Industries Ltd. and Can Do MS,
Published by
Business Wire
02 Nov 17 Teva Announces Completion of Plan B One-Step® Divestiture to Foundation Consumer Healthcare Teva Pharmaceutical Industries Ltd.,
Published by
Business Wire
01 Nov 17 Teva Announces Completion of PARAGARD® Divestiture to CooperSurgical Teva Pharmaceutical Industries Ltd.,
Published by
Business Wire
31 Oct 17 Teva Wins Generic Uceris® Patent Trial Teva Pharmaceutical Industries Ltd.,
Published by
Business Wire
30 Oct 17 Kåre Schultz to Join Teva as President and Chief Executive Officer on November 1, 2017 Teva Pharmaceutical Industries Ltd.,
Published by
Business Wire
19 Oct 17 Teva to Highlight New Data in Multiple Sclerosis at Joint ECTRIMS – ACTRIMS Congress in Paris Teva Pharmaceutical Industries Ltd.,
Published by
Business Wire
17 Oct 17 Teva Announces Submission of Biologics License Application for Fremanezumab to the U.S. FDA Teva Pharmaceutical Industries Ltd.,
Published by
Business Wire
10 Oct 17 Teva to Report Third Quarter 2017 Financial Results on November 2, 2017 Teva Pharmaceutical Industries Ltd.,
Published by
Business Wire
04 Oct 17 Teva Comments on Anticipated At-Risk U.S. Launch of Generic Glatiramer Acetate 40mg/mL and Launch of Generic Glatiramer Acetate 20mg/mL Teva Pharmaceutical Industries Ltd.,
Published by
Business Wire
03 Oct 17 Teva Announces Reintroduction of Generic Depo-Provera® in the United States Teva Pharmaceutical Industries Ltd.,
Published by
Business Wire
19 Sep 17 Teva and Nuvelution Pharma Partner to Accelerate Development of AUSTEDO® (deutetrabenazine) Tablets for Use in Tourette Syndrome in the United States Teva Pharmaceutical Industries Ltd.,
Published by
Business Wire
19 Sep 17 Teva Completes Amendment to Credit Facilities Teva Pharmaceutical Industries Ltd.,
Published by
Business Wire
18 Sep 17 New Initiative Creates Scalable Solutions to Improve Care of Patients with Multiple Chronic Conditions Teva Pharmaceutical Industries Ltd.,
Published by
Business Wire
18 Sep 17 Teva Announces Sale of Remaining Assets in Specialty Global Women’s Health Portfolio for $1.38 Billion Teva Pharmaceutical Industries Ltd.,
Published by
Business Wire
12 Sep 17 Teva Receives FDA Priority Review for First Line Use of TRISENOX® (arsenic trioxide) in Patients with Low to Intermediate Risk Acute Promyelocytic Leukemia (APL) Teva Pharmaceutical Industries Ltd.,
Published by
Business Wire
11 Sep 17 Teva Announces Sale of PARAGARD® (intrauterine copper contraceptive) to CooperSurgical Teva Pharmaceutical Industries Ltd.,
Published by
Business Wire
11 Sep 17 Teva Names Kåre Schultz as President and Chief Executive Officer Teva Pharmaceutical Industries Ltd.,
Published by
Business Wire
09 Sep 17 Teva Showcases Data Demonstrating Potential of Fremanezumab to Address Significant Unmet Need in Patients with Chronic and Episodic Migraine Teva Pharmaceutical Industries Ltd.,
Published by
Business Wire
28 Jul 17 Teva Announces Launch of Generic Epiduo® in the United States Teva Pharmaceutical Industries Ltd.,
Published by
Business Wire
13 Jul 17 Teva Enhances Board of Directors as All Proposals Approved at Annual General Meeting of Shareholders Teva Pharmaceutical Industries Ltd.,
Published by
Business Wire
20 Jul 17 NICE Recommends CINQAERO® (reslizumab) for the Treatment of Severe Eosinophilic Asthma Teva Pharmaceutical Industries Ltd.,
Published by
Business Wire
29 Jun 17 Teva Announces Publication of AIM-TD Study Results in The Lancet Psychiatry for the Investigational Use of Deutetrabenazine in Tardive Dyskinesia Teva Pharmaceutical Industries Ltd.,
Published by
Business Wire
31 Jul 17 Celltrion and Teva Announce U.S. FDA Acceptance of Biologics License Application for Proposed Biosimilar to Herceptin® (trastuzumab) Teva Pharmaceutical Industries Ltd.,
Published by
Business Wire
24 Jul 17 Teva Announces the Launch of Generic Vagifem® in the United States Teva Pharmaceutical Industries Ltd.,
Published by
Business Wire
30 Aug 17 Teva Announces FDA Approval of AUSTEDO® (deutetrabenazine) Tablets for the Treatment of Tardive Dyskinesia in Adults Teva Pharmaceutical Industries Ltd.,
Published by
Business Wire
11 Jul 17 Teva and the Huntington Study Group Announce Publication of Data for AUSTEDO™ (deutetrabenazine) Tablets in Huntington Disease from ARC-HD Study in JAMA Neurology Teva Pharmaceutical Industries Ltd.,
Published by
Business Wire
05 Sep 17 Teva to Present Fremanezumab Data on Migraine Prevention at the 18th Congress of the International Headache Society Teva Pharmaceutical Industries Ltd.,
Published by
Business Wire
18 Aug 17 Teva Announces Exclusive Launch of Generic Axiron® in the United States Teva Pharmaceutical Industries Ltd.,
Published by
Business Wire
11 Jul 17 Teva to Report Second Quarter 2017 Financial Results on August 3, 2017 Teva Pharmaceutical Industries Ltd.,
Published by
Business Wire
07 Aug 17 Teva Announces FDA Approval of QVAR® RediHaler™ (Beclomethasone Dipropionate HFA) Inhalation Aerosol Teva Pharmaceutical Industries Ltd.,
Published by
Business Wire
Advertising
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.